** Shares of Applied Therapeutics APLT.O fall 80.3% to $1.70 after the bell
** Company says the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic metabolic disease
** The FDA's letter to the company said the marketing application for the drug, govorestat, cannot be approved in its current form, due to certain deficiencies - APLT
** Galactosemia can cause neurological complications, including deficiencies in speech, cognition, behavior and motor skills
** Up to last close, stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.